UTILITY PATENT APPLICATION TRANSMITTAL

(only for new non-provisional applications under 37 CFR §1.53(b))

19587 U.S. PTO 10/721210

Mail Stop Patent Application Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Transmitted herewith for filing is the patent application under 37 CFR 1.53(b) of:

AVENTIS DOCKET NO.: ST01018G1 US CNT

INVENTORS: Hervé Bouchard, et al

TITLE: Chemical Derivatives and Their

Application As Antitelomerase Agent

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on Date of Poposit

Express Mail No.

APPLICATION ELEMENTS

1.	\boxtimes	*Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing)		·
2.		Specification (preferred arrangement set forth below) - Descriptive title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to Microfiche Appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure	Total Pages	68
3.		Drawing(s) (35 U.S.C. 113)	Total Sheets	
4.	Oath	or Declaration	Total Pages	2
	a.	Newly unexecuted (original or copy)		
	b.	Copy from a prior application (37 CFR § 1	.63(d))	
		i. DELETION OF INVENTOR(S) Signed statement attached deleting application, see 37 CFR §§ 1.63(d)(2)		ned in the prior
5.	Powe	er of Attorney	Total Pages	
	a.	Newly executed (original or copy)	J	
	b.	Copy from a prior application (37 CFR § 1	.63(d))	
6.		Microfiche Computer Program (Appendix)		

Page 2							
(if applicable, all necessary) a. Computer Readable Copy b. Paper Copy (identical to c	a. Computer Readable Copy b. Paper Copy (identical to computer copy)						
Continuation Divisional of prior application no: PCT/FR02/01 Examiner, Group/Art Unit	Continuation Divisional Continuation-in-part of prior application no: PCT/FR02/01767, filed May 27, 2002,						
FR01 06909, filed May 28, 2001, and	This application claims the benefit of French Patent Application No. FR01 06909, filed May 28, 2001, and FR02 01256, filed February 4, 2002. (The cross reference has been/will be inserted on page one of the specification).						
application is enclosed.) The entire disclosure of the prior app supplied, is considered as being part							
ACCOMPANYING APPLICATION PARTS	3						
7. Assignment Papers (cover sheet							
8. 37 CFR §3.73(b) Statement (when there is an assignee)	. 37 CFR §3.73(b) Statement						
9.							
10. Information Disclosure Copies of IDS Citations Statement (IDS)/PTO-1449							
11. Preliminary Amendment	•						
12. Return Receipt Postcard (MPE (Should be specifically itemized							
13. Small Entity Statement(s) (PTO/SB/09-12)	Statement filed in prior application, Status still proper and desired						
14. Certified Copy of Priority Document(s) FR 0106909 and FR 0201256 (if foreign priority is claimed)							
15. Other: Application Data Shee	et (3 pgs.)						
CORRESPONDENCE ADDRESS							
Customer Number or Bar Code Label	005487						
	(Insert Customer No. or Attach bar code label here)						
	A. A. 1.12 C. A						
	Balaram Gupta, Reg. No. 40,009						
	Attorney/Agent for Applicant						

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-3364
Telefax (908) 231-2626
Aventis Docket No. ST01018G1 US CNT

Application Transmittal Letter

Approved for use through 04/30/2003. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE collection of information unless it displays a yalid OMB control number.

			Complete if Known				
FEE TRANS	IVIIIIAL	Application Number	Not Yet Assign d				
		Filing Date	Concurrently Filed Herewith				
for FY 2	2003	First Named Inventor	Herv´ Bouchard, et al				
Patent fees are subject to a	annual revision.	Examiner Name					
Applicant claims small entity status.	See 37 CFR 1.27	Group / Art Unit					
TOTAL AMOUNT OF PAYMENT	(\$) 1,094.00	Attorney Docket No.	ST01018G1 US CNT				

METHOD OF PAYMENT (check all that apply)				FEE CALCULATION (continued)					
Check Credit Card Money Other None				3. A[ODITIO	NAL F	EES		
Order Deposit Account				Large E	•	Small E			
Deposit Account		18-1982		Fee Code	Fee (\$)	Fee Code	Fee (\$)		
Number L Deposit	Number 10-1702				. ,			Fee Description	Fee Paid
Account Name	Aventis	s Pharmaceuticals In	ic.	1051	130	2051	65	Surcharge - late filing fee or oath	
The Commissi		ized to: (check all tha						Surcharge - late provisional filing fee or	
· ·) indicated below		-	1052 1053	50 130	2052 1053	25 130	cover sheet Non-English Specification	
	` '	uring the pendency of this		1812	2,520	1812	2,520	For filing a request for reexamination	
	s) indicated below, e-identified deposi	, except for the filing fee t account	•	1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
	FEE CAL	CULATION		1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1. BASIC FIL			_	1251	110	2251	55	Extension for reply within first month	
Large Entity Fee Fee Code (\$)	Fee Fee Code (\$)	Fee Description	Fee Paid	1252	420	2252	205	Extension for reply within second month	
1001 770	2001 375	Utility filing fee	770	1253	950	2253	465	Extension for reply within third month	
1002 340	2002 165	Design filing Fee		1254	1,480	2254	725	Extension for reply within fourth month	
1003 530	2003 260	Plant filing fee		1255	2,010	2255	985	Extension for reply within fifth month	
1004 770	2004 375	Reissue filing fee		1401	330	2401	160	Notice of Appeal	
1005 160	2005 80	Provisional filing fee		1402	330	2402	160	Filing a brief in support of an appeal	
SUBTOTAL (1) (\$) 770.00			1403	290	2403	140	Request for oral hearing		
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE			1451	1,510	1451	1,510	Petition to institute a public use proceeding		
	Ex	Fee dra from	Fee	1452	110	2452	55	Petition to revive - unavoidable	
_		aims below	Paid						
Total Claims 38		18 x 18	= 324	1453	1,330	2453	650	Petition to revive - unintentional	
Independent 3	- 3**=	0 x 0	= 0	1501	1,330	2501	650	Utility issue fee (or reissue)	
Claims				1502 1503	480 640	2502 2503	235 315	Design issue fee Plant issue fee	
Multiple Dependen	nt	0	= 0	1460	130	· 1460	130	Petitions to the Commissioner	
Large Entity	Small Entity	_		1807	50	1807	50	Petitions related to provisional	
Fee Fee Code (\$)	Fee Fee Code (\$)	Fee Description						applications	
1202 18	2202 9	Claims in excess of 20		1806	180	1806	180	Submission of Information Disclosure Stmt	
1201 86	2201 42	Independent claims in	excess of 3	8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1203 290	2203 140	Multiple dependent cla	im, if not	1809	770	2809	375	Filing a submission after final rejection (37 CFR § 1.129(a))	
1204 86	2204 42	**Reissue independent claims over original p	atent	1810	770	2810	375	For each additional invention to be examined (37 CFR § 1.129(b))	
1205 18 2205 9 **Reissue claims in excess of 20 and over original patent				1801	770	2801	375	Request for Continued Examination (RCE)	
				1802	900	1802	900	Request for expedited examination of a design application	
SUBTOTAL (2) (\$) 324.00				Other fee	(specify)				
**or number previously paid, if greater; For Reissues, see above			*Reduced by Basic Filing Fee Paid			Paid	SUBTOTAL (3) (\$)		

SUBMITTED BY Complete (If applicable)								
Name (Print/Type)	Balaram Gupta, Reg. No. 40,009	Registration No. (Attomey/Agent)	40,009	Telephone	(908) 231-3364			
Signature	Belaram Guph			Date	MOV. 25,2003			

WARNING: Informati n on this form may becom public. Credit card information sh uld n t be

included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Alexandra, VA 22313. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandra,